No Data
JMP Securities Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $288
BeiGene: Strong Revenue Outlook and Innovative Cancer Treatments Drive Buy Recommendation
Hong Kong stocks news preview this week: multiple domestic macroeconomic data to be released, Alibaba and Tencent will disclose their third quarter reports.
1. Multiple domestic macroeconomic data are coming, which ones are worth paying special attention to? 2. Alibaba and Tencent will disclose their third-quarter reports, what are the market expectations?
Most pharmaceutical stocks rose, with Tongyuan Kangyi Medicine (02410) up 18.46%. Institutions pointed out that the policy trend of medical insurance funds supporting innovative drugs will not change.
Jingwu Cai Xun | Most pharmaceutical stocks rose, with Tongyuan Kang Medicine (02410) up 18.46%, Keji Pharmaceutical (02171) up 13.86%, Heyu (02256) up 11.79%, Cloud Peak Xin Yao (01952) up 10.31%, cansinobio (06185) up 7.48%. Zhong Yin International stated that benefiting from overseas interest rate cuts and domestic macroeconomic improvement, the pharmaceutical industry, as a high elasticity industry, is expected to outperform the market. The bank believes that the performance of the macroeconomy is closely related to the revenue and expenditure of medical insurance funds and medical health consumer spending. As policy focus shifts to stimulating the economy, the bank believes that medical industry
BeiGene to Present at the Jefferies London Healthcare Conference
Express News | U.S.-Listed Shares of Chinese Firms Drop Premarket on Worries Over Growing U.S.-China Trade Tensions Under Trump Presidency
No Data
No Data
